Intellia Therapeutics, Inc. Profile Avatar - Palmy Investing

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the …
Biotechnology
US, Cambridge [HQ]
Government, Law & Regulation

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Intellia Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
0.0 IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
YoY Trends
  • No trends presentable at the moment.

Spending By Type

Awards
Obligations
Contracts IDV Contracts Grants Loans Direct Other

Intellia Therapeutics, Inc. can't present spending by time.

Contract Analysis

There are no contract award details available for Intellia Therapeutics, Inc.

End of NTLA's Analysis
CIK: 1652130 CUSIP: 45826J105 ISIN: US45826J1051 LEI: - UEI: -
Secondary Listings
NTLA has no secondary listings inside our databases.